Verily’s Onduo Branches into Mental and Behavioral Health

Onduo launched as a joint venture between Verily and Sanofi.

Omar Ford

June 1, 2021

2 Min Read
IMG_May282021at20723PM.jpg
MohamadFaizal -stock.adobe.com

Verily’s Onduo is branching into mental and behavioral health. Onduo virtual telehealth clinic, achieves this goal by allowing individuals are able to access psychiatrists, therapists, and mental health coaches.

“Access to behavioral health services is often a challenge and has become an even greater need during the pandemic,” explained Onduo’s CEO, Vindell Washington, MD. “We also know that individuals often do not recognize symptoms of depression or seek help. This solution is an important extension of the Onduo services for our customers’ members and employees so that we get them matched to the right mental health care support.”

Onduo identifies each individual’s needs and then matches them to the right care pathway using a novel whole health assessment within its predictive analytics framework built by its parent company Verily. Onduo’s offerings include digital well-being journeys, activities, and health coaching. If clinically indicated, members will meet with an Onduo clinician to discuss therapy or psychiatry options through telemedicine—all embedded within the Onduo app.

Onduo evaluates changes over time to step-up and step-down care, as needed, and helps individuals track progress over time and improve their quality of life. Onduo’s solution aims to deliver measurable reductions in depressive symptoms and improvements in managing work and home responsibilities, which is a direct tie to absenteeism.

Ondou was formed in 2016 as a joint venture between Verily and Sanofi each investing nearly $500 million. At the time, both Verily and Sanofi said Onduo’s mission is to help people with diabetes live full, healthy lives by developing comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management.

However, in December of 2019, Sanofi’s newly installed CEO, Paul Hudson, announced the company had “over-invested” in Onduo. The company said it would focus on immunology and vaccine businesses and stop its work in cardiovascular and diabetes R&D efforts.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like